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Summary
It is not well established whether haemorheological alterations
constitute independent risk factors for deep vein thrombosis
(DVT).We have determined in 149 DVT patients and in 185 con-
trol subjects the body mass index (BMI), the haemorheological
profile: blood viscosity (BV), plasma viscosity (PV), fibrinogen
(Fg), erythrocyte aggregation (EA), erythrocyte deformability
(ED) and plasma lipids. In the crude analysis BMI, Fg, PV, EA, trig-
lycerides (TG) andApoB were statistically higher and HDL cho-
lesterol (HDL-Chol) statistically lower in DVT patients than in
controls.No differences in BV and ED were observed.After BMI
adjustment, Fg, PV and EA remained statistically higher in DVT
cases than in controls (P=0.013; P=0.012; P=0.013; P=0.028, re-
spectively).When the risk of DVT associated with these vari-
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ables (using cut-offs that corresponded to the mean plus one SD
of the control group) was estimated,EA>8.2 and PV>1.28 mPa
.
s
were significantly associated with DVT even further adjustment
for lipids and obesity (OR=2.78,P=0.004;OR=1.91,P=0.024,re-
spectively). However, PV did not remain statistically significant
after additional adjustment for Fg.When we consider together
all the analyzed variables in order to control every variable for
each other,TG>175 mg/dl (OR=3,2,P=0.004) and BMI>30 kg/m
2
(OR=3.5, P=0.003), were also independently associated with a
greater risk of DVT. Our results suggest that increased EA con-
stitute an independent risk factor for DVT. However, when as-
sociated to hyperlipidaemia and obesity it further increases
thrombotic risk.
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Introduction
Deep vein thrombosis (DVT) is a multifactorial disease in which
inherited and acquired risk factors play an important pathogenic
role (1). Since Virchow, it is assumed that blood flow alterations
(haemorheological alterations) may favour the development of
venous thrombus (2). The rheological hypothesis for venous
thrombogenesis is supported by the association of many risk fac-
tors for DVT with systemic rheological alterations (3, 4) and the
association of some rheological variables with DVT in case-con-
trol studies (5–10). However, there is not enough evidence to
prove that haemorheological alterations constitute independent
risk factors for DVT when patients are evaluated out of the acute
phase, when the temporary fibrinogen increase (the protein
which modulates most of the haemorheological parameters) is
strongly marked. Moreover, studies conducted so far consist
mainly of a small sample size (6, 7, 9, 11, 12), do not determine
all the rheological parameters (5–8, 10), do not exclude patients
with malignant, inflammatory, autoimmune or infectious dis-
eases (11, 12) that entail marked fibrinogen increases and, in ad-
dition, they do not always consider the presence of concomitant
classical cardiovascular risk factors, i.e. obesity, hypertension,
diabetes, dyslipidaemia and tobacco (6–9, 11, 12), which can not
be overlooked as they affect rheological blood behaviour, acting
as confounders. In particular, both obesity (13–18) and hyper-
lipidaemia (16, 19–26) appear to be associated with a two- to
four-fold increased risk of DVT. The prothrombotic pathogenic
mechanisms of obesity, as well as hyperlipidemia, are not clearly
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established. One possible mechanism could be by modifying the
blood flow characteristics, given that lipids and fibrinogen,
which are increased in both conditions, may modulate most of
the haemorheological parameters.
The aim of the present study was to assess the overall hae-
morheological profile six to 12 months after the acute episode in
patients with DVT, i.e. blood viscosity (BV), plasma viscosity
(PV) and erythrocyte aggregation (EA) and deformability (ED),
to find out whether some haemorheological parameters consti-
tute independent risk factors for DVT and to determine whether
the lipid alterations themselves or those due to obesity could
modify rheological parameters and thus promote DVT.
Materials and methods
Study group
One hundred and forty-nine patients with previously docu-
mented DVT (86 male, 63 female) aged 42 ± 12 years were re-
ferred to our Haemorheology and Thrombosis Unit between Ja-
nuary 2003 and October 2006. They all had experienced a first
DVT episode six to 12 months before sampling (mean, 9 ± 3
months). Exclusion criteria were: organic, malignant, infectious,
autoimmune or inflammatory diseases, i.e. those pathologies
that could influence rheological profile, as well as treatment with
rheological drugs. Those patients with inherited (antithrombin,
protein C or protein S deficiency, factor V Leiden, prothrombin
G20210A mutation) or acquired (lupus anticoagulant or anticar-
diolipin antibodies) thrombophilic risk factors were also ex-
cluded as their thromboembolic episodes could be explained by
haemostatic abnormalities.
The control group was made up of 185 subjects (aged 42 ± 13
years, 89 male, 96 female) undergoing a routine check up at our
hospital, without a previous history of DVT confirmed with a
validated questionnaire (27). Cardiovascular risk factors were
recorded and considered for both groups. These included obesity
(body mass index [BMI] >30 kg/m
2
), current tobacco use (>1
cigarette/day), hypertension (diastolic blood pressure >90
mmHg), hyperlipidaemia (total cholesterol >220 mg/dl and/or
triglycerides >175 mg/dl), fasting glucose >126 mg/dl, or were
receiving any pharmacological treatment for hypertension, hy-
perlipidaemia, or diabetes. Subjects gave their informed consent
to participate in the study, which was approved by the Hospital
Ethics Committee.
Circumstantial patient thrombotic risk factors, i.e. medical
(oral contraceptives, varicose veins, pregnancy, bed rest >1
week, heart failure, chronic obstructive pulmonary disease,
obesity, etc), surgery, immobilization, and trauma were recorded
(secondary DVT), and those thrombotic events that occurred
without any circumstantial risk factor were considered sponta-
neous DVT. From the 149 DVT patients, 111 showed some cir-
cumstantial risk factors (75%) and 38 did not (25%). In the 111
DVT patients, the percentages of circumstantial risk factors were
as follows: medical 41.7%, surgical 17.5%, immobilisation
20.5% and trauma 20.3%. In addition, 16 of the 149 DVT pa-
tients had a pulmonary embolism (PE). DVT was documented
with ultrasonography or venography, and PE with ventilation
perfusion scanning, pulmonary angiography, or helicoidal com-
puterised tomography.
Blood collection
Blood was collected at least six months after the acute event
(range 6–12 months; mean: 9 ± 3 months). After a 12-hour over-
night fast, blood was drawn between 8 and 10 a.m. by venipunc-
ture into standard vacuum tubes containing EDTA K
3
for rheo-
logical and haematological measurements, 0.1 vol of 0.129 M
trisodium citrate as an anticoagulant for fibrinogen measure-
ment, or into plain tubes for glucose and lipids determination.
Rheological parameters were examined within 2 hours of blood
collection, to avoid deterioration of the rheological red blood cell
properties (28).
Laboratory methods
Blood viscosity (BV) was determined in a Brookfield DVIII vis-
cosimeter (Engineering, Stougthon MA, USA) at native and
45% corrected hematocrit with autologous plasma, at two shear
rates of 230 s
-1
and 23 s
-1
, at 37ºC. Plasma viscosity (PV) was
measured in a capillary plasma viscosimeter (Fresenius GmbH,
Germany) at 37ºC (29). Erythrocyte aggregation (EA) was deter-
mined in a Myrenne MA
1
aggregometer (Myrenne, GmbH,
Roetgen, Germany) (30) after adjusting the haematocrit to 45%
with autologous plasma, during completed stasis (EA
0
) and
while the sample was subjected to a low shear rate of 3 s
-1
(EA
1
).
The greater the tendency of red blood cell to aggregate, the
higher the aggregability index. Erythrocyte deformability (ED)
was determined in a Rheodyn shear stress diffractometer (My-
renne GmbH) at 12, 30 and 60 Pascals (31). The higher the ery-
throcyte elongation index (EEI), the more deformable the red
blood cell is. Fibrinogen (Fg) was measured using coagulometric
techniques on an ACL7000 autoanalyser (Instrumentation Lab-
oratory, Milan, Italy). Haematocrit was measured by microcen-
trifugation at 15,000 x g for 10 minutes.
Total cholesterol (T-Chol), low-density lipoprotein-choleste-
rol (LDL-Chol), high-density lipoprotein-cholesterol (HDL-
Chol), triglycerides, and glucose were measured by enzymatic
techniques, using a DAX 72 autoanalyser (Bayer Diagnostics
Division, Tarrytown, NY, USA). Apolipoproteins AI and B were
quantified by immunonephelometry (Dade Behring, Marburg
GmbH, Germany).
Basic haematological parameters and red cell indices, in-
cluding mean cell volume (MCV), mean haemoglobin concen-
tration (MHC), and mean corpuscular haemoglobin concen-
tration (MCHC), were measured in a Sysmex ME 8.000 autoana-
lyser (TOA Medical Electronics, Kobe, Japan).
BV was determined in a random sample of 102 cases and 105
controls and ED in 40 cases and 59 controls. Cases and controls
were well matched for age and sex. Patients and controls samples
were processed simultaneously.
Statistical analysis
All continuous variables were checked for normal distribution.
TG, glucose and Fg values were log-transformed for statistical
testing. The data are expressed as mean ± one standard deviation
(SD). Student's t-test was used to assess the mean differences in
continuous variables between patients and control subjects, and
Chi
2
-tests were used to compare differences in percentages be-
tween patients and controls. Pearson correlation coefficients
were calculated to describe the bivariate correlation among vari-
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ables. Multiple lineal regression analysis (covariance method)
was used to adjust for the influence of BMI or the other param-
eters on the unadjusted differences of means in lipids, fibri-
nogen, plasma viscosity and erythrocyte aggregation between
DVT patients and controls. In these analyses, we used different
models depending on the adjusted variable. First, we adjusted
each variable that was statistically significant in the crude model
for all the other variables that were statistically significant in the
unadjusted analysis. Taking into account that after these adjust-
ment BMI was the only variable that remained highly signifi-
cant, we fitted additional multivariate models in which each lipid
and haemorheological parameters were only adjusted for BMI.
Logistic regression models (crude and adjusted for potential
confounders) were fitted to estimate the odds ratio (OR) and
95% confidence interval (CI) of DVT associated with the pres-
ence of obesity and/or the other haemorheological parameters. In
these analyses, dichotomised variables according to cut-off
points that corresponded to the mean plus one SD of the control
group were used. Standard regression diagnostic procedures
were used to ensure the appropriateness of the models.
For statistical inference, a bilateral p-value <0.05 was con-
sidered statistically significant. All analyses were calculated
using the Statistical Package for Social Sciences (SPSS, version
14) for Windows.
Results
Table 1 shows the percentage of DVT patients and controls with
cardiovascular risk factors. DVT patients showed a higher per-
centage of hyperlipidaemia (46% vs. 35%, P=0.040) and obesity
(23% vs. 6%, P=0.001) than controls. When hypercholesterole-
mia (T-Chol >220 mg/dl) and hypertriglyceridemia (TG
>175 mg/dl) were considered separately, DVT patients showed a
borderline increased percentage of hypercholesterolemia
(P=0.040) and a higher percentage of hypertriglyceridemia
(P=0.001). The percentage of hypertensives, diabetics and
smokers was similar in DVT patients and control subjects.
Table 2 shows BMI, glucose, lipids and haemorheological
parameters in the 149 DVT patients and 185 control subjects.
Only BMI,TG,Apo B, B/AI ratio, Fg, PV, EA
0
and EA
1
were sig-
nificantly higher and HDL-Chol lower in cases than in controls.
After multivariate adjustment for the potential confounding fac-
tors, only BMI remained significantly different (P<0.001). After
adjusting for BMI, only Fg, PV, EA
0
and EA
1
remained signifi-
cantly different between patients and controls.
No statistical differences in rheological parameters were ob-
served between patients with spontaneous and secondary DVT.
No differences in erythrocyte indices were observed between
patients and controls (MCV: 91 ± 10 vs. 90 ± 5 fl, P= 0.782;
MCH: 31 ± 2 vs. 30 ± 2 pg, P= 0247; MCHC: 33 ± 1 vs. 33 ± 1%,
P=0.875). The Pearson bivariate correlations between haemor-
heological and lipid parameters were statistically significant
(P<0.01) between EA
1
and BMI (r=0.334), T-Chol (r=0.268),
LDL-Chol (r=0.269), Apo B (r=0.344), TG (r=0.356), Fg
(r=0.355), PV (r=0.412) and there was a negative correlation be-
tween EA
1
and HDL-Chol (r=-0.152) (P<0.05 in all cases). In
addition, PV correlated with BMI (r=0.196), Apo B (r=0.186),
TG (r=0.153) , and Fg (r=0.508) (P<0.01), and T-Chol (r=0.136)
(P<0.05).
Given the multiple correlations between the rheological pa-
rameters, lipids and BMI, to estimate the risk of obesity associ-
ated with these parameters, a logistic regression analysis was
carried out. Instead of continuous variables, dichotomized vari-
ables (according to cut-off points that corresponded to the mean
plus one SD of the control group) were used for the analysed pa-
rameters to better estimate the risk associated with high values.
Crude and multivariate models were estimated for each variable.
Table 3 shows OR of DVT associated with haemorheological pa-
rameters (EA
1
>8.2, PV>1.28 mPa
.
s, Fg>320 mg/dl) and obesity
(BMI>30 kg/m
2
). In the crude Model I all parameters were sig-
nificantly associated with a higher risk of DVT. This association
remained statistically significant even further adjustment for li-
pids (Model II) and BMI (Model III). When PV was additionally
adjusted for Fg (Model IV) this parameter did not remained stat-
istically significant. However, EA
1
, BMI and Fg remained statis-
tically significant in Model IV.
Moreover, when we considered together all the analysed vari-
ables in order to control every variable for each other and to know
whether they constitute independent risk factors for DVT, we ob-
tained that TG >175 mg/dl (OR=3.2, 95% CI=1.4–7.3,
P=0.004), Fg>320 mg/dl (OR=2.7, 95% CI=1.3–5.6, P=0.008),
EA
1
>8.2 (OR=2.8, 95% CI=1.3–5.9, P=0.007) and BMI >30
kg/m
2
(OR=3.5, 95% CI=1.5–8.1, P=0.003), but not PV >1.28
mPa
.
s nor T-Chol >220 mg/dl remained significantly associated
with DVT. Therefore TG, Fg, EA
1
and BMI constitute indepen-
dent risk factors for DVT when they reach high values (higher
than mean plus one SD).
Discussion
The results obtained in the present study indicate that DVT pa-
tients do not show a higher BV compared to the control group,
Table 1: Age, gender, BMI and incidence (%) of cardiovascular
risk factor in DVT patients and controls.
DVT
(n= 149)
Controls
(n= 185)
P
Age (mean ± SD) 42 ± 12 42 ± 13 0.982
Male/female 86/63 89/96 0.082
BMI (kg/m
2
) 27.6 ± 4.23 24.5 ± 3.5 0.001
*Hyperlipidaemia (%) 46 35 0.040
**Hypercholesterolemia (%) 45 33 0.040
***Hypertriglyceridemia (%) 18.7 05.7 0.001
Obesity (%) 23 06 0.001
Hypertension (%) 13.5 08.2 0.114
Diabetes (%) 04.2 02.2 0.326
Tobacco (%) 31.1 38 0.183
* T-Chol>220 mg/dl and/or TG>175 ml/dl or were receiving any pharmacological treatment.
** T-Chol >220 mg/dl or were receiving any pharmacological treatment.
*** TG>175 ml/dl or were receiving any pharmacological treatment.
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both at native and 45% corrected haematocrit. Little information
is available on DVT case-control studies regarding BV evalu-
ation. Our results agree with those previously reported (5, 6, 9,
11, 12) in not having found differences between both groups. It is
well known that BV, when determined at high shear rate, is a glo-
bal rheological parameter, depending on haematocrit, Fg con-
centration and ED. Given that DVT patients in the present study
did not show a lower ED either, it is reasonable that, at the shear
rates used (230 s
-1
and 23 s
-1
) where BV basically depends on ED,
the former did not show any significant difference with respect
to the control group. The significant increase in Fg observed in
cases compared with controls does not seem to be high enough to
produce significant increases in BV. Our results agree with sev-
eral studies where DVT patients show significant Fg increases
even three months or more after the acute event (5, 6, 8–12). In
line with these results, in the population-based case control study
Table 2: BMI, glucose, li-
pids and haemorheological
parameters in DVT pa-
tients and controls.
DVT
(n= 149)
Controls
(n= 185)
Haematocrit (%) 043 ± 4 042 ± 4
Plasma viscosity (mPa
.
s) 001.25 ± 0.07 001.22 ± 0.06
Erythrocyte aggregation
stasis
003.85 ± 1.28 003.46 ± 1.02
Erythrocyte aggregation 3s
-1
007.58 ± 1.36 006.99 ± 1.17
Native bloodViscosity 230s
-1
(mPa
.
s) 004.34 ± 0.58 004.29 ± 0.52
Native Blood viscosity 23s
-1
(mPa
.
s) 006.61 ± 1.0 006.43 ± 1
Corrected BloodViscosity 230s
-1
(mPa
.
s) 004.63 ± 0.39 004.61 ± 0.31
Corrected blood viscosity 23s
-1
(mPa
.
s) 007.09 ± 0.69 007.06 ± 0.61
Erythrocyte elongation index 12 Pa (%) 047 ± 3 047 ± 4
Erythrocyte elongation index 30 Pa (%) 053 ± 3 054 ± 4
Erythrocyte elongation index 60 Pa (%) 056 ± 3 057 ± 3
Values expressed as mean ± SD. *The corresponding P-value of each variable was adjusted for the other variables that were statistically significant in the un-
adjusted analysis. **The corresponding P-value was adjusted only for BMI.
BMI (kg/m
2
) 027.6 ± 4.23 024.5 ± 3.5
Glucose (mg/dl) 091 ± 14 090 ± 14.34
Total cholesterol (mg/dl) 211 ± 47 203 ± 37
HDL-Cholesterol (mg/dl) 050 ± 15 055 ± 13
LDL-Cholesterol (mg/dl) 133 ± 38 130 ± 34
Triglycerides (mg/dl) 127 ± 91 094 ± 48
Apo AI (mg/dl) 144 ± 32 145 ± 25
Apo B (mg/dl) 103 ± 30 095 ± 23
B/AI 000.74 ± 0.26 000.67 ± 0.21
Fibrinogen (mg/dl) 282 ± 72 252 ± 46
Unadjusted
P-value
0.001
0.486
0.144
0.010
0.478
0.001
0.716
0.016
0.020
0.001
0.184
0.001
0.002
0.001
0.493
0.225
0.656
0.756
0.648
0.462
0.220
Adjusted
<0.001
0.651
0.519
0.300
0.514
0.987
0.168
-----
0.798
0.195
-
0.132
-
0.883
0.803
0.013
0.012
0.013
0.028
*P-value **P-value
Table 3: Risk of DVT associated with haemorheological parameters and BMI. Crude and adjusted models.
Model IV adjusted***
P OR (95% CI) P
EA
1
>8.2 0.004 2.85 1.35–6.01 0.006
PV>1.28 0.024 1.47 0.81–2.71 0.205
Fg>320 0.001 +2.91 1.42–5.94 0.004
BMI>30 ---- ++4.19 1.84–9.52 0.001
Units: PV: mPa
.
s; Fg: mg/dl; BMI: kg/m
2
. * Model II. Adjusted for lipids: T-Chol > 220 mg/dl and TG > 175 mg/dl. ** Model III. Adjusted for lipids and BMI > 30 kg/m
2
. *** Model IV. Adjusted for lipids, BMI > 30 kg/m
2
and Fg > 320 mg/dl. +Adjusted for lipids and BMI > 30 kg/m
2
. ++Adjusted for lipids and Fg > 320 mg/dl.
Model I unadjusted
OR
2.64
2.29
4.40
4.64
(95% CI)
1.42–4.93
1.40–3.86
2.29–8.48
2.26–9.53
P
0.002
0.002
<0.001
<0.001
Model II adjusted*
OR
2.70
2.09
4.31
5.12
(95% CI)
1.37–5.37
1.21–3.59
2.20–8.45
2.32–11.3
P
0.004
0.008
<0.001
<0.001
Model III adjusted**
OR
2.78
1.91
3.32
----
(95% CI)
1.38–5.60
1.09–3.37
1.66–6.67
-----
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conducted by Koster (8), in which 199 patients with a first DVT
episode were compared with 199 healthy subjects, those with
plasma Fg higher than 500 mg/dl had an almost four-fold in-
creased risk of DVT.
With respect to ED, as mentioned, we did not observe differ-
ences between cases and controls at any of the shear stresses
tested. There have been no studies published, so far, where this
rheological parameter has been evaluated using ektacytometric
techniques, as in the present one. Previous studies (32, 33) that
found controversial results regarding ED in DVT patients, used
older filtration methods that may be influenced by extra-erythro-
cytic factors such as remnant leucocytes, red blood cell aggre-
gates or plasma factors (34, 35), whereas ektacytometry does
not.
As regards the other rheological parameters analysed in the
present study, it is important to highlight that DVT patients have
shown increased PV and EA when compared with controls. It is
known that both rheological parameters are influenced by plas-
ma lipids (10, 36–39) and Fg levels (40–42), which have also
shown to be increased in our study. Additionally, obesity is also
associated with increased Fg and TG levels (14, 16, 21, 43–46).
In the present study, the risk associated with obesity (BMI
≥30 kg/m
2
) was 3.5 (95% CI 1.5–8.1), which is in line with pre-
vious studies carried out by our group where the risk of DVT as-
sociated with obesity was 2.5 (95% CI 1.2–5.1) (16). For this rea-
son, the first question we should consider is: Is the increase in
these rheological parameters, PV and EA, due to an independent
increase in Fg and lipids or is their increase associated to obes-
ity? In other words, if patients with DVT were not obese: Would
they still have increased PV and EA? Our logistic regression
models (Table 3) indicate that EA
1
> 8.2 and PV > 1.28 mPa
.
s
were significantly associated with DVT even further adjustment
for lipids (Model II) and obesity (Model III). These results sug-
gest that PV and EA are increased in DVT patients independently
of lipid levels and the obesity status. However, PV did not remain
statistically significant after additional adjustment for Fg
(Model IV), given the high influence of Fg on this rheological
parameter.Therefore, in DVT patients EA
1
>8.2 constitutes a risk
factor for DVT, increasing the risk even though patients would
not be obese. However, the fact of being obese would further in-
crease the risk.
Several authors have also found EA to be increased in DVT
patients 12 months after the acute event (6, 10–12). Some re-
searchers have found higher EA only in those patients with per-
sistent thrombotic risk factors but not in those with transient
thrombotic risk factors (11). In this sense, we have not observed
any differences in this rheological parameter in connection with
the nature of the thrombotic episode, i.e. spontaneous or second-
ary DVT. It must be emphasised that some studies include pa-
tients with malignancy (11, 12) where increased Fg could have
been responsible for erythrocyte hyperaggregability. Other au-
thors (7) performed the study six weeks after the acute episode,
where the acute phase could have influenced results and, in addi-
tion, most studies did not measure plasma lipids which may also
account for erythrocyte hyperaggregability. In our study, the in-
fluence of acute phase or malignancy has been excluded, and the
role played by lipids on EA has also been evaluated, allowing us
to conclude that, according to our logistic regression analysis,
EA
1
>8.2 is an independent thrombotic risk factor, increasing the
risk almost three times.
As regards PV in DVT patients, only some studies did deter-
mine this rheological parameter, finding it to be normal (9, 10) or
increased (5, 6) in association with higher cholesterol and TG
levels (5). Moreover, Balendra et al. (5) reported PV to be an in-
dependent risk factor for DVT. Although the present study has
found PV to be increased in DVT patients and associated with li-
pids and mostly with Fg levels, it does not constitute an indepen-
dent risk factor for DVT (Model IV). This is consistent with the
pathophysiology of the different thrombotic locations, as in-
creases in PV mostly promote thrombus development in the
microcirculatory areas and small arteries, whereas increases in
EA promote thrombus formation in low-shear areas such as
pocket valves in the lower extremities.
In conclusion, the results obtained in the present study, per-
formed in a large group of patients with a DVT episode in the
previous 6–12 months, allow us to conclude that rheological pa-
rameters play a role in the pathogenesis of the thrombotic event.
Increased EA constitute a risk factor for DVT independently of
lipid levels and obesity status. However, when associated with
hyperlipidaemia and obesity it further increases thrombotic risk.
It is reasonable to advise losing weight and to decrease plasma
lipid levels in order to reduce DVT risk.
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